BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38003353)

  • 21. Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization.
    Lloyd RV; Cano M; Chandler WF; Barkan AL; Horvath E; Kovacs K
    Am J Pathol; 1989 Mar; 134(3):605-13. PubMed ID: 2466405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-occurrence of Pituitary Neuroendocrine Tumors (PitNETs) and Tumors of the Neurohypophysis.
    Saeger W; von Schöning J; Flitsch J; Jautzke G; Bergmann M; Hagel C; Knappe UJ
    Endocr Pathol; 2021 Dec; 32(4):473-479. PubMed ID: 34129177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up.
    Ferrés A; Reyes L; Di Somma A; Topczewski T; Mosteiro A; Guizzardi G; De Rosa A; Halperin I; Hanzu F; Mora M; Alobid I; Aldecoa I; Bargalló N; Enseñat J
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A clinicomorphological study of pituitary tumors associated with the clinical syndrome of acromegaly.
    Andreeva M; Georgiev T; Bosadjieva E; Karagiosov L; Karagiosov K; Tomova A; Matrosov P; Kirilov G; Diankov L; Christova T
    Exp Clin Endocrinol; 1991; 98(3):223-7. PubMed ID: 1778242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Characteristics, Diagnosis, and Treatment of Thyroid Stimulating Hormone-Secreting Pituitary Neuroendocrine Tumor (TSH PitNET): A Single-Center Experience.
    Heo J; Suh YL; Kim SH; Kong DS; Nam DH; Lee WJ; Kim ST; Hong SD; Ryu S; Lee YB; Kim G; Jin SM; Kim JH; Hur KY
    Endocrinol Metab (Seoul); 2024 Apr; 39(2):387-396. PubMed ID: 38311828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plurihormonal Pituitary Neuroendocrine Tumors: Clinical Relevance of Immunohistochemical Analysis.
    Dumitriu-Stan RI; Burcea IF; Dobre R; Nastase VN; Ceausu RA; Raica M; Poiana C
    Diagnostics (Basel); 2024 Jan; 14(2):. PubMed ID: 38248047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.
    Buurman H; Saeger W
    Eur J Endocrinol; 2006 May; 154(5):753-8. PubMed ID: 16645024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
    Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
    Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basic fibroblastic growth factor stimulates prolactin secretion from human anterior pituitary adenomas without affecting adenoma cell proliferation.
    Atkin SL; Landolt AM; Jeffreys RV; Diver M; Radcliffe J; White MC
    J Clin Endocrinol Metab; 1993 Sep; 77(3):831-7. PubMed ID: 8370706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plurihormonal (TSH-GH-prolactin Secreting) PIT-1-Positive pituitary Macroadenoma/Pituitary Neuroendocrine Tumor (PitNET) Associated with Graves' Disease: A Case Report.
    Morgante C; Guaraldi F; Asioli S; Mazzatenta D; Papi G; Pontecorvi A
    Endocr Metab Immune Disord Drug Targets; 2023; 23(12):1557-1561. PubMed ID: 37357515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas.
    Rubinfeld H; Hadani M; Barkai G; Taylor JE; Culler MD; Shimon I
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2257-63. PubMed ID: 16595604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of postoperative biochemical remission in lower Knosp grade growth hormone-secreting pituitary adenomas: a large single center study.
    Zhang S; Chen J; Yao S; Akter F; Wang Z; Hu B; Zhu D; Duan C; Chen W; Zhu Y; Wang H; Mao Z
    J Endocrinol Invest; 2023 Mar; 46(3):465-476. PubMed ID: 36125731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum prolactin and growth hormone response to thyrotropin-releasing hormone in patients with pituitary adenomas.
    Chang CC; Chen FW; Hsieh HC
    Taiwan Yi Xue Hui Za Zhi; 1989 May; 88(5):443-9. PubMed ID: 2507734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical Analyses of Mammalian Target of Rapamycin (mTOR) Expression in Pituitary Neuroendocrine Tumors (PitNETs): mTOR as a Therapeutic Target for Functional PitNETs.
    Nakazato I; Shiomi T; Oyama K; Matsuno A; Inomoto C; Yoshiyuki Osamura R
    Acta Histochem Cytochem; 2023 Dec; 56(6):121-126. PubMed ID: 38318106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
    Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
    Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone and prolactin gene expression in human densely and sparsely granulated somatotroph adenomas by in situ hybridization with digoxigenin-labeled probes.
    Yamada S; Takahashi M; Hara M; Sano T; Aiba T; Shishiba Y; Suzuki T; Asa SL
    Diagn Mol Pathol; 1994 Mar; 3(1):46-52. PubMed ID: 8162255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
    Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
    Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
    Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
    Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients.
    Esposito V; Santoro A; Minniti G; Salvati M; Innocenzi G; Lanzetta G; Cantore G
    Neurol Sci; 2004 Dec; 25(5):251-6. PubMed ID: 15624082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features and analysis in 1385 Chinese patients with pituitary adenomas.
    Shao S; Li X
    J Neurosurg Sci; 2013 Sep; 57(3):267-75. PubMed ID: 23877272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.